AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Onco-Nephrology

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5301/jo-n.5000030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

  2017cited by this paper
• Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.

  2016cited by this paper
• A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use

  2016cited by this paper
• Current Trends of Renal Impairment in Multiple Myeloma

  2016cited by this paper
• Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.

  2016cited by this paper
• Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

  2016cited by this paper
• Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

  2015cited by this paper
• Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both

  2015cited by this paper
• Bortezomib-induced acute interstitial nephritis.

  2015cited by this paper
• Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

  2015influential reference
• A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide

  2014cited by this paper
• Carfilzomib‐Associated Tumor Lysis Syndrome

  2014cited by this paper
• Minimal change disease and lenalidomide.

  2013cited by this paper
• Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

  2013cited by this paper
• The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.

  2013cited by this paper
• Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies

  2013cited by this paper
• Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center.

  2013cited by this paper
• Carfilzomib-related acute kidney injury.

  2013cited by this paper
• Onco-nephrology: tumor lysis syndrome.

  2012cited by this paper
• Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

  2012cited by this paper
• Mechanisms of light chain injury along the tubular nephron.

  2012cited by this paper
• Bortezomib-induced thrombotic thrombocytopaenic purpura

  2012cited by this paper
• Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.

  2012cited by this paper
• How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing.

  2012cited by this paper
• The biology of immunoglobulin free light chains and kidney injury.

  2011cited by this paper
• Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

  2011cited by this paper
• Renal improvement in myeloma with bortezomib plus plasma exchange.

  2011cited by this paper
• Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.

  2010cited by this paper
• Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

  2009influential reference
• Autologous hematopoietic stem-cell transplantation for multiple myeloma.

  2009cited by this paper
• Screening panels for detection of monoclonal gammopathies.

  2009cited by this paper
• VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

  2009cited by this paper
• Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.

  2008cited by this paper
• Reversible Fanconi syndrome due to lenalidomide

  2008cited by this paper
• Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

  2008cited by this paper
• Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma

  2008cited by this paper
• Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.

  2007cited by this paper
• Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival

  2007cited by this paper
• The evolving background for high-dose treatment for myeloma

  2007cited by this paper
• Multiple myeloma.

  2006cited by this paper
• Bortezomib-induced tumor lysis syndrome in multiple myeloma.

  2006cited by this paper
• Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.

  2006cited by this paper
• Clinical practice. Hypercalcemia associated with cancer.

  2005cited by this paper
• Plasma Exchange When Myeloma Presents as Acute Renal Failure

  2005cited by this paper
• Pathophysiology of myeloma bone disease

  2004cited by this paper
• AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells

  2004cited by this paper
• A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

  2003cited by this paper
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

  2003cited by this paper
• Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

  2003cited by this paper
• Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia

  2003cited by this paper
• Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

  2001cited by this paper
• Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score

  2000cited by this paper
• Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory.

  2000cited by this paper
• Renal failure in multiple myeloma: reversibility and impact on the prognosis

  2000cited by this paper
• Heavy chain deposition disease: the disease spectrum.

  1999cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies.

  1995cited by this paper
• Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.

  1995cited by this paper
• Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta.

  1995cited by this paper
• Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis

  1995cited by this paper
• Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients

  1994cited by this paper
• Acute renal failure in the setting of bone marrow transplatation

  1994cited by this paper
• Overrepresentation of the V kappa IV subgroup in light chain deposition disease.

  1994influential reference
• Acute renal failure in the setting of bone marrow transplantation.

  1994cited by this paper
• Overrepresentation of the VϰIV subgroup in light chain deposition disease

  1994cited by this paper
• Pathobiology of cast nephropathy from human Bence Jones proteins.

  1992cited by this paper
• On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion

  1990cited by this paper
• Glomerular blood flow after single nephron obstruction in the rat kidney.

  1986cited by this paper

• Hypercalcemia-induced hypokalemic metabolic alkalosis with hypophosphatemia in a multiple myeloma patient: lessons for the clinical nephrologist

  2022cites this paper
• Preventive strategies for acute kidney injury in cancer patients

  2020cites this paper
• Atypical urinary crystals in a patient with acute kidney injury

  2019cites this paper
• Monoclonal immunoglobulin–mediated kidney disease: What is beyond amyloidosis in real practice?

  2019cites this paper
• Acute Kidney Injury in Cancer Patients.

  2018cites this paper